MYOK News and Press, MyoKardia Inc. From 11/09/20

Merger activity remained steady last week with four new deals announced. The acquisition of Endurance International Group Holdings by Clearlake Capital Group. The acquisition of Navistar International Corporation by TRATON SE. For further details see: Merger Ar...

MyoKardia (MYOK): Q3 GAAP EPS of -$1.60 misses by $0.12.Cash, cash equivalents and investments of $895.9MStock -0.08%.Press Release For further details see: MyoKardia EPS misses by $0.12

BRISBANE, Calif., Nov. 05, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today reported financial results for the third quarter ended September 30, 2020. Recent Clinical Program Highlights Mavacamten for Hypertrophic Cardiomyopathy (HCM) EXPLORER-HCM ...

Bristol-Myers is acquiring MyoKardia for $225. HSR-waiting period passed yesterday. The deal could close within the next two weeks. Annualized returns is quite attractive while odds of a deal break are low. For further details see: MyoKardia: Safe But Fleeting Expect...

BRISBANE, Calif., Nov. 04, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced three awardees of the 2020 MyoSeeds™ Research Grant Program, who have been selected to receive $250,000 each in support of original, independent research in the biology and underlying m...

Bristol Myers Squibb (NYSE: BMY) and MyoKardia, Inc. (Nasdaq: MYOK) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb’s previously announced tender offer to acqu...

The pharmaceutical industry is famous for generating enormous profits with help from patent-protected exclusivity, but those protections don't last forever. In order to produce steadily growing profits, Bristol Myers Squibb (NYSE: BMY) has been buying up drugmakers large and small. ...

BRISBANE, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the upcoming presentation of clinical and non-clinical data related to mavacamten, MyoKardia’s investigative therapeutic in late-stage development for the potential treatment of hypertr...

NEW YORK, NY / ACCESSWIRE / October 29, 2020 / Halper Sadeh LLP, a global investor rights law firm, announces it is investigating: CIT Group Inc. (NYSE:CIT) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to First...

MYOK may have seemed an expensive and unwanted use of cash at first, but it couldn't have been too bad for management to have bought it. Indeed, successfully raising clinical awareness for HCM and R&D successes will have made the acquisition a good bargain. We can determine th...